Background {#Sec1}
==========

The taxonomy of the genus *Leishmania* is complex and has been revised several times in light of parasite biology and biochemistry \[[@CR1], [@CR2]\]. Currently, the genus *Leishmania* includes four subgenera: *Leishmania*, *Viannia*, *Sauroleishmania* and *L. enriettii* complex. Each subgenus includes several species \[[@CR1]\]. *Leishmania infantum*, the aetiological agent of visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL), belongs to subgenus *Leishmania* \[[@CR3]\].

Multilocus enzyme electrophoresis (MLEE) is the isoenzymatic analysis presently considered the reference method for parasite typing by the World Health Organization \[[@CR4]\]. This technique, developed at the Centre for Leishmaniasis of Montpellier (France), is based on the electrophoretic mobility of several enzymes obtained from promastigote culture, as described by Rioux et al. \[[@CR5]\]. Up to 15 enzymes can be considered in this analysis: malate dehydrogenase, malic enzyme, isocitrate dehydrogenase (NADP), phosphogluconate dehydrogenase, glucose-6-phosphate dehydrogenase, glutamate dehydrogenase, cytochrome-b5 reductase, purine-nucleoside phosphorylase 1 and 2, glutamic-oxaloacetic transaminase 1 and 2, phosphoglucomutase, fumarase, mannose-6-phosphate isomerase, and glucose-6-phosphate isomerase \[[@CR6]\]. The comparison of isoenzyme mobility with a reference strain identified over 300 zymodemes, also termed MON.

Concerning *L. infantum*, 45 zymodemes have been found, 36 recognized as real zymodemes and 9 as variants \[[@CR6]\]. In dogs in the Mediterranean area, 12 zymodemes have been found: MON-1, MON-24, MON-34, MON-72, MON-77, MON-80, MON-98, MON-105, MON-108, MON-199, MON-199 variant NP1130 and MON-281. With the exception of MON-105, these zymodemes have also all been found in humans \[[@CR6]\]. Other zymodemes, such as MON-11, MON-27, MON-28, MON-29 MON-33 and MON-189, have been isolated only from humans \[[@CR7]\]. *Leishmania infantum* MON-1 is the most frequent zymodeme in both humans and dogs in the Mediterranean basin \[[@CR8]\] and in the New World \[[@CR9]\]. It is present in 30 countries and represents about 70% of all identified strains. In particular, MON-1 represents 88% of *L. infantum* zymodemes in the south of France \[[@CR10]\], 96.7% in Portugal \[[@CR11]\] and 45--58% in Spain \[[@CR12], [@CR13]\]. Moreover, in HIV-infected subjects, MON-1 was found in about 73% of co-infections, while in immunocompetent patients it was found in about 90% of VL cases and 20% of CL cases \[[@CR14]\]. Concerning canine infections in Italy, Gramiccia et al. \[[@CR15]\] showed a high prevalence of MON-1 zymodeme (91%) in 497 canine clinical isolates, with the remaining percentage composed almost exclusively of MON-72 zymodeme. The homogeneity of the isoenzymes identified in the dog population does not fully reflect the isoenzyme diversity in humans; therefore, the role of canine population as the only reservoir for all *L. infantum* zymodemes remains unclear. In light of this epidemiological evidence, it is advisable that a more extensive typing of *L. infantum* be carried out. However, MLEE presents several disadvantages: it is time-consuming, technically demanding, and requires bulk cultures of parasites. Moreover, due to its inability to detect nucleotide substitutions that do not change the amino acid composition, its discriminatory power is poor. Therefore, molecular approaches such as multilocus microsatellite typing (MLMT) \[[@CR16], [@CR17]\] and multilocus sequence typing (MLST) \[[@CR18]--[@CR20]\] have been introduced for strain discrimination. MLST results were generally in agreement with MLEE, though increased resolution was obtained and some key discrepancies were found \[[@CR18]--[@CR21]\]. For example, *L. infantum* zymodeme MON-1 has been shown to be genetically heterogeneous. On the other hand, it was also shown that strains classified as different zymodemes can present the same genotype \[[@CR18], [@CR20]\]. However, the low number of typed strains and the lack of consensus on the marker genes, as well as the lack of MLST database for *Leishmania*, have hindered the implementation of MLST as a reference typing method \[[@CR22]\]. Until now, most of the epidemiological data available in the literature is based on MLEE classification, and many DNA-based typing methods correlate data with existing MLEE classification \[[@CR23], [@CR24]\].

In this study, we explored the sequences of seven *L. infantum* genes encoding enzymes considered in MLEE analysis with the aim of (i) enriching the actual databases; (ii) identifying polymorphisms that characterize *L. infantum* zymodemes most prevalent in the Mediterranean basin; and (iii) developing a rapid screening test that would give results that could be associated with existing MLEE data, overcoming the drawbacks of this laborious technique.

Methods {#Sec2}
=======

*Leishmania infantum* DNA {#Sec3}
-------------------------

*Leishmania infantum* strains or isolates used in this study are listed in Table [1](#Tab1){ref-type="table"}. The Chelex-purified DNA from promastigotes of *L. infantum* strains or isolates was obtained from the National Reference Center for Leishmaniasis (C.Re.Na.L.), Istituto Zooprofilattico Sperimentale della Sicilia (Palermo, Italy). The DNA was quantified using a Qubit fluorometer (Life Technologies, Carlsbad, USA).Table 1*Leishmania infantum* strains/isolates used in this studySpeciesStrain or clinical isolateZymodeme*L. infantum*MHOM/TN/80/IPT1MON-1*L. infantum*MHOM/FR/78/LEM75MON-1*L. infantum*Clinical isolate V2921MON-1*L. infantum*Clinical isolate 31UMON-1*L. infantum*Clinical isolate 49UMON-1*L. infantum*Clinical isolate 10816MON-1*L. infantum*Clinical isolate 791MON-1*L. infantum*MHOM/DZ/82/LIPA59MON-24*L. infantum*MHOM/ES/81/BCN1MON-29*L. infantum*MHOM/IT/86/ISS218MON-72*L. infantum*MHOM/IT/93/ISS822MON-201*L. infantum*Isolate 1Not determined*L. infantum*Isolate 2Not determined

Identification of molecular targets and PCR amplification {#Sec4}
---------------------------------------------------------

A preliminary *in silico* analysis was performed in the GenBank sequence database to search for genes encoding enzymes used in MLEE for *L. infantum*. These genes were selected not only to gain information on genetic diversity, but also to connect the genotyping results to the existing MLEE data. Six genes were initially selected, based on previous studies performed on *L. infantum* that allowed the retrieval of available polymorphic sequences from GenBank, i.e. malic enzyme (*me*), 6-phosphogluconate dehydrogenase (*pgd*), mitochondrial isocitrate dehydrogenase (*icd*), glucose-6-phosphate isomerase (*gpi*), glucose-6-phosphate dehydrogenase (*g6pdh*) and mannose phosphate isomerase (*mpi*). Moreover, the phosphoglucomutase (*pgm*) gene was also taken into consideration in an attempt to enrich the existing database. Primers were designed with Primer-BLAST \[[@CR25]\] using *L. infantum* MHOM/FR/78/LEM75 or MCAN/AR/10/MDP1 sequences as reference. The primers are listed in Table [2](#Tab2){ref-type="table"} and their position on the seven target genes are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.Table 2Primers used in this studyTarget geneGenBank IDForward primer (5\'-3\')Reverse primer (5\'-3\')Amplicon length (bp)Malic enzyme^a^DQ449701.1GAGCCGATCAACCGCTATCATCTTTCTTCATCCCGGCCTC773Malic enzyme^b^DQ449701.1GGTGTGGCGGAGAGCATCTTGTTGCCTTGCGATGGTTG458Malic enzyme^c^DQ449701.1TCAGAACCTTCGCAAGACGACACTTGCCGATGCTGATGC111Phosphogluconate dehydrogenaseAM157139.1TTCGGCTTCGACAACGATCACGAGGGAAGTTGGGGAATG306Mitochondrial isocitrate dehydrogenaseDQ449672.1CTCCAGCACCAACGTCTACCTACATGCGCTGGAAGGTCTG708Glucose-6-phosphate isomeraseAJ620617.1CATTCACCAGGGCACCAAGATGATCGGAGACGATGTTGCC426Glucose-6-phosphate dehydrogenaseDQ449770.1ATGTCGGAAGAGCAGTCTCACTCCTTCCCGAGGTAGTGGT765PhosphoglucomutaseKJ643214.1GGAGACGGTTAAGATTACGCACTATGCTTCATCGCGGGGTT413Mannose phosphate isomeraseDQ449737.1TTTGCGGAGTTGTGGGTAGGCTCGCTGCTCTTCTTCTCGT864^a^5\' region^b^3\' region^c^Internal region

Conventional PCR was performed on a total volume of 50 μl with 1--2 μl of template, 200 μM dNTP, 2.5 mM MgCl~2~, 200 nM of each primer and 1 unit of Hot-Rescue DNA polymerase (Diatheva s.r.l., Fano, Italy). The amplification was performed in a PCR GeneAmp 2700 thermocycler (Applied Biosystems, Foster City, USA). The thermal cycling profile was as follows: 94 °C for 7 min; followed by 35 cycles at 94 °C for 30 s, 60 °C for 20 s or 60 s (depending on amplicon length) and 72 °C for 20 s; with a final extension at 72 °C for 5 min. Each sample was amplified in duplicate. Amplified fragments were analyzed by agarose gel electrophoresis and visualized with GelRed DNA stain (Biotium, Fremont, USA). The gels were visualized under UV light using a gel doc apparatus (Bio-Rad, Hercules, USA). A 100-bp double-stranded DNA ladder or ΦX174 DNA/BSU/ HaeIII/marker 9 (MBI Fermentas, Waltham, USA) was included on the gels as a size standard.

PCR product sequencing and phylogenetic analysis {#Sec5}
------------------------------------------------

The amplification products of *me*, *pgd*, *icd*, *gpi*, *g6pdh*, *mpi* and *pgm* genes for all the strains/isolates are indicated in Table [1](#Tab1){ref-type="table"} (with the exception of isolate 1 and isolate 2) were purified using a Minelute PCR purification kit (Qiagen, Hilden, Germany) and directly sequenced. DNA sequencing was performed using the BigDye Terminator v. 1.1 Cycle Sequencing Kit on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Bases with Phred values \< 20 were checked by visual analysis of electropherograms and aligned with BioEdit Sequence Alignment Editor \[[@CR26]\] using default options. Heterozygosity was considered to be present when direct sequencing of PCR product yielded a similar peak at the same site. The sequences were deposited in GenBank with the following accession numbers: MF375413-MF375423 (*me*), MF280205-MF280215 (*pgd*), MF347625-MF347635 (*icd*), MF288905-MF288915 (*gpi*), MF479731-MF479741 (*g6pdh*), MF462101-MF462111 (*mpi*) and MF347614-MF347624 (*pgm*).

For each housekeeping gene, allele numbers were assigned to unique sequences and a genotype was determined as the combination of the six genes selected for analysis (Additional file [2](#MOESM2){ref-type="media"}: Table S1). In total, 54 isolates/strains belonging to 22 different MON, were analyzed; 23 of them had sequences available for *me*, *pgd*, *icd*, *gpi*, *g6pdh* and *mpi* genes. For each of these isolates/strains, we concatenated those sequences to obtain a 3578 bp-long sequence. A maximum likelihood tree was constructed from the concatenated nucleotide dataset using PhyML 3.0 \[[@CR27]\]. The best-fit substitution model was determined by the Akaike information criterion (AIC) using Smart Model Selection \[[@CR28]\]. The optimal model of evolution was GTR+I with proportion of invariable sites of 0.989 and one category for substitution rate. Bootstrap values were calculated from 100 replications. The tree was visualized using iTOL \[[@CR29]\].

Real-time PCR and high resolution melting (HRM) analysis {#Sec6}
--------------------------------------------------------

A 111 bp internal region of the *me* gene encompassing the single nucleotide polymorphism (SNP) 390T\>G was amplified with primers listed in Table [2](#Tab2){ref-type="table"}. Real-time PCR (named qPCR-MEint) was carried out in a 25 μl volume with 1 μl template DNA and SYBR green PCR master mix (Diatheva s.r.l.) containing 1U Taq Polymerase and 200 nM of each primer. The PCR reactions were performed in a Rotor-Gene 6000 instrument (Corbett Life Science, Mortlake, Australia). The amplification profile was: 94 °C for 10 min; followed by 33 cycles at 94 °C for 30 s, 60 °C for 20 s and 72 °C for 20 s. The reactions were performed in duplicate. After amplification, the high-resolution melting (HRM) analysis was performed over the range 85--95 °C, rising by 0.1 °C/s and waiting for 2 s at each temperature. Raw HRM curves were normalized by the Rotorgene 6000 v.1.7 software. Difference graphs of the normalized curves were obtained using MHOM/FR/78/LEM75 and MHOM/DZ/82/LIPA59 strains as reference curves for genotypes 390T and 390G, respectively.

The qPCR-MEint and HRM analysis was also tested using DNA extracted from 4 clinical samples (whole blood, buffy coat, conjunctival swabs, bone marrow aspirate) as described previously \[[@CR30], [@CR31]\]. To ensure adequate sensitivity with these samples, a pre-amplification step (10 cycles) was performed and 2 μl of pre-amplified mixture were used as template in the qPCR described above.

Results {#Sec7}
=======

Sequence analyses {#Sec8}
-----------------

The *L. infantum* isolates/strains gave single products of expected size with the primer pairs listed in Table [2](#Tab2){ref-type="table"}. The PCR products were sequenced and the sequences were aligned with those obtained from GenBank. Partial sequences of *me*, *pgd*, *icd*, *gpi*, *g6pdh*, *mpi* and *pgm* genes were obtained from 11 strains/isolates of *L. infantum*. Seven represented MON-1 zymodeme and the remaining four represented MON-24, MON-29, MON-72 and MON-201 (Table [1](#Tab1){ref-type="table"}). Notably, the following *L. infantum* sequences from zymodemes not previously reported in the databases were obtained: *me* sequences from MON-24, MON-72 and MON-201; a *pgd* sequence from MON-201; *icd* sequences from MON-24, MON-72 and MON-201; *gpi* sequences from MON-24, MON-72 and MON-201; *g6pdh* sequences from MON-24, MON-72 and MON-201; *mpi* sequences from MON-24, MON-72 and MON-201; and *pgm* sequences from MON-1, MON-24, MON-29, MON-72 and MON-201.

Concerning the *me* gene, 13 SNPs were evidenced (Table [3](#Tab3){ref-type="table"}). Nine were silent and four changed the amino acid sequence (V59M; I133S; V330I; E563E/D). These data confirmed previously reported findings obtained with *L. donovani* complex \[[@CR19]\]. All sequences from MON-1 strains were identical, except for the MHOM/TN/80/IPT1 strain. Notably, the genotype heterogeneity of this strain was previously confirmed on the *gpi* sequence \[[@CR18]\]. It is also noteworthy that the two MON-29 strains (MHOM/ES/82/BCN1 and MHOM/FR/1996/LEM3249) showed differences at nucleotide positions 327, 329 and 507, confirming the higher discriminatory power of a sequencing approach compared to MLEE. The *pgd* gene sequence showed only the silent SNP 678A\>G in 11 strains (Table [4](#Tab4){ref-type="table"}). Concerning the *icd* gene, it is of relevance that two silent SNPs (204T\>C, 369T\>C) were evidenced in strain MHOM/DZ/82/LIPA59 (MON-24) and three silent SNPs (150G\>A, 369T\>C, 1038C\>A) in strain MHOM/SD/1997/LEM3472 (MON-267) (Table [5](#Tab5){ref-type="table"}). The polymorphisms 204T\>C and 1038C\>A appeared unique for MON-24 and MON-267, respectively. The *gpi* gene sequence showed 1503G\>T/K and 1831G\>A/R SNPs in 4 and 5 strains, respectively (Table [6](#Tab6){ref-type="table"}). The *g6pdh* gene showed 8 SNPs (Table [7](#Tab7){ref-type="table"}). The *mpi* gene showed 5 SNPs (Table [8](#Tab8){ref-type="table"}), with SNP 486G\>A unique for MON-136. Finally, concerning the *pgm* gene, no differences were found among the zymodemes examined, including the two sequences available in the database.Table 3Polymorphisms in malic enzyme (*me*) geneZymodemeStrain/isolateGenBank ID106204327329390507586762843919118212871620MON-1MHOM/FR/78/LEM75DQ449701.1GCCTTTCCCGACGMON-1MHOM/ES/1993/PM1DQ449703.1**.............**MON-1MHOM/FR/1995/LPN114DQ449702.1**.............**MON-1MHOM/PT/2000/IMT260DQ449706.1**.............**MON-1MHOM/FR/1997/LSL29DQ449704.1**.............**MON-1MHOM/ES/1986/BCN16DQ449705.1**.............**MON-1MHOM/BL/67/ITMAP263KU175196.1**............**--**MON-1MHOM/TN/80/IPT1MF375413**--**...**G**....**--------**MON-1MHOM/FR/78/LEM75MF375414**--**........**--------**MON-1Isolate 31UMF375415**--**........**--------**MON-1Isolate 49uMF375416**--**.....--..**--------**MON-1Isolate 10816MF375417**--**........**--------**MON-1Isolate 791MF375418**--**........**--------**MON-1Isolate V2921MF375419**--------------**..**--------MON-11MHOM/FR/1980/LEM189DQ449714.1**....**G**........MON-24MHOM/DZ/82/LIPA59MF375420**--T**.**GGG**..**T--------**MON-29MHOM/ES/82/BCN1MF375421**--**.**MGGG**...**--------MON-29MHOM/FR/1996/LEM3249DQ449707.1**....**G**........MON-72MHOM/IT/86/ISS218MF375422**--**...........**--MON-78MHOM/MT/1985/BUCKDQ449715.1--**..**GGG**...**ACT**.**MON-81MHOM/SD/1962/3S^a^DQ449718.1--**..**GGGAG**.**A**...**MON-98MHOM/GR/2001/GH6DQ449728.1**....**G**........**MON-98MCAN/GR/2001/GD8DQ449729.1**....**G**........**MON-98MHOM/GR/2003/GH15DQ449730.1**....**G**........**MON-98MHOM/GR/2003/GH16DQ449731.1**....**G**........**MON-98MHOM/GR/2003/GH18DQ449732.1**....**G**........**MON-98MHOM/GR/2003/GH20DQ449733.1**....**G**........**MON-98MHOM/GR/2004/GD17DQ449734.1**....**G**........**MON-183MHOM/ES/1991/LEM2298DQ449708.1**....**G**........**MON-188MHOM/IT/1993/ISS800DQ449722.1**.**T**.**GGG**..**TA**...**MON-198MHOM/ES/1988/LLM175DQ449719.1**....**G**........**MON-199MHOM/ES/1992/LLM373DQ449720.1A**..**GGG**....**C**..MON-201MHOM/IT/93/ISS822MF375423............**--MON-228MHOM/IT/1994/ISS1036DQ449721.1**....**G**.......**SMON-267MHOM/SD/1997/LEM3472^a^DQ449723.1**...**GGG**...**A**...**MON-309ITOB/TR/2005/CUK2EU545253.1**.**T**.**KGG**..**YA**...**MON-309MHOM/TR/2005/CUK1EU545252.1**.**T**.**GGG**..**TA**...**niITOB/TR/2007/CUK10EU545254.1**.**T**.**KGG**..**YA**...**non-MON-1MHOM/TR/2000/OG-VLEU545255.1**....**G**........**niIsolate RRR-BDQ449727.1**....**G**........**Zymodeme sequences obtained in this study are in bold*Abbreviation*: *ni* not indicated*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]Table 4Polymorphisms in 6-phosphogluconate dehydrogenase (*pgd*)ZymodemeStrain/isolateGenBank ID194678747MON-1MHOM/FR/78/LEM75AM157139.1CACMON-1MHOM/PT/2000/IMT260 (LEM3975)AM157144.1**...**MON-1MHOM/ES/1986/BCN16 (LEM1078)AM157143.1**...**MON-1MHOM/FR/1997/LSL29 (LEM3420)AM157142.1**...**MON-1MHOM/ES/1993/PM1 (LEM2608)AM157141.1**...**MON-1MHOM/FR/1995/LPN114 (LEM3001)AM157140.1**...**MON-1MHOM/TN/1980/IPT1AM157736.1**...MON-1MHOM/TN/1980/IPT1MF280205**--**..MON-1Isolate 31uMF280206**--**..MON-1Isolate 49uMF280207**--**..MON-1Isolate 791MF280208**--**..MON-1Isolate 10816MF280209**--**..MON-1MHOM/FR/78/LEM75MF2802010**--**..MON-1Isolate V2921MF2802011**--**..**MON-11MHOM/FR/1980/LEM189AM157151.1**.**G**.MON-24MHOM/DZ/82/LIPA59MF2802012**--G**.**MON-24IARI/PT/1989/IMT171AM157137.1**.**G**.**MON-27MHOM/IT/1979/FrancescaAM157138.1**...MON-29MHOM/ES/82/BCN1MF2802013**--G**.**MON-29MHOM/FR/1996/LEM3249AM157145.1**.**G**.**MON-34MHOM/CN/1980/AAM157136.1**.**G**.MON-72MHOM/IT/86/ISS218MF2802014**--**..**MON-78MHOM/MT/1985/BUCKAM157152.1**...**MON-81MHOM/SD/1962/3S^a^AM157155.1TGTMON-183MHOM/ES/1991/LEM2298AM157146.1**.**G**.**MON-188MHOM/IT/1993/ISS800AM157159.1**.**G**.**MON-198MHOM/ES/1988/LLM175AM157156.1**.**G**.**MON-199MHOM/ES/1992/LLM373AM157157.1**.**G**.MON-201MHOM/IT/93/ISS822MF2802015**--**..**MON-228MHOM/IT/1994/ISS1036AM157158.1**.**G**.**MON-267MHOM/SD/1997/LEM3472^a^AM157160.1TGTZymodeme sequences obtained in this study are in bold*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]Table 5Polymorphisms in mitochondrial isocitrate dehydrogenase (*icd*)ZymodemeStrain/isolateGenBank ID1502043691038MON-1MHOM/FR/78/LEM75DQ449672.1GTTCMON-1MHOM/ES/1986/BCN16DQ449676.1**....**MON-1MHOM/FR/1997/LSL29DQ449675.1**....**MON-1MHOM/ES/1993/PM1DQ449674.1**....**MON-1MHOM/FR/1995/LPN114DQ449673.1\|**....**MON-1MHOM/PT/2000/IMT260DQ449677.1**....MON-1MHOM/TN/1980/IPT1MF347625...**--**MON-1MHOM/FR/78/LEM75MF347626...**--**MON-1Isolate 31uMF347627...**--**MON-1Isolate 49uMF347628...**--**MON-1Isolate 791MF347629...**--**MON-1Isolate 10816MF347630...**--**MON-1Isolate V2921MF347631...**--MON-11MHOM/FR/1980/LEM189DQ449685.1**..**C**.MON-24MHOM/DZ/82/LIPA59MF347632.**CC--**MON-29MHOM/ES/82/BCN1MF347633...**--MON-29MHOM/FR/1996/LEM3249DQ449678.1**..**C**.MON-72MHOM/IT/86/ISS218MF347634...**--MON-78MHOM/MT/1985/BUCKDQ449686.1**..**C**.**MON-81MHOM/SD/1962/3S^a^DQ449689.1A**.**C**.**MON-183MHOM/ES/1991/LEM2298DQ449679.1**....**MON-188MHOM/IT/1993/ISS800DQ449693.1**..**C**.**MON-198MHOM/ES/1988/LLM175DQ449690.1**....**MON-199MHOM/ES/1992/LLM373DQ449691.1**....MON-201MHOM/IT/93/ISS822MF347635...**--MON-228MHOM/IT/1994/ISS1036DQ449692.1**..**C**.**MON-267MHOM/SD/1997/LEM3472^a^DQ449694.1A**.**CAMON-309ITOB/TR/2005/CUK2EU545241.1**..**C**.**MON-309MHOM/TR/2005/CUK1EU545240.1**..**C**.**niITOB/TR/2007/CUK10EU545242.1**..**C**.**non-MON-1MHOM/TR/2000/OG-VLEU545243.1**....**niniDQ449698.1**....**Zymodeme sequences obtained in this study are in bold*Abbreviation*: *ni* not indicated*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]Table 6Polymorphisms in glucose-6-phosphate isomerase (*gpi*)ZymodemeStrain/isolateGenBank ID703150318071831MON-1MHOM/FR/1978/LEM75AJ620617.1TGCGMON-1MHOM/TN/1980/IPT1AJ620647.1**...**AMON-1MHOM/PT/2000/IMT260AM157725.1**....**MON-1MHOM/ES/1986/BCN16AM157724.1**....**MON-1MHOM/FR/1997/LSL29AM157723.1**....**MON-1MHOM/ES/1993/PM1AM157722.1**....**MON-1MHOM/FR/1995/LPN114AM157721.1**....MON-1MHOM/TN/1980/IPT1MF288905**--**.**----**MON-1MHOM/FR/78/LEM75MF288906**--**.**----**MON-1Isolate 31uMF288907**--**.**----**MON-1Isolate 49uMF288908**--**.**----**MON-1Isolate 791MF288909**--**.**----**MON-1Isolate 10816MF288910**--**.**----**MON-1Isolate V2921MF288911**--**.**----**MON-24MHOM/DZ/82/LIPA59MF288912**--**.**----MON-27MHOM/IT/1979/FrancescaAM117192.1**...**R**MON-29MHOM/ES/82/BCN1MF288913**--**.**----MON-29MHOM/FR/1996/LEM3249AJ620618.1**....**MON-34MHOM/CN/1980/AAJ620637.1**...**A**MON-72MHOM/IT/86/ISS218MF288914**--**.**----MON-78MHOM/MT/1985/BUCKAJ620619.1**...**AMON-81MHOM/SD/1962/3S^a^AJ620629.1C**.**T**.**MON-183MHOM/ES/1991/LEM2298AJ620620.1**.**T**..**MON-198MHOM/ES/1988/LLM175AJ620630.1**.**T**..**MON-199MHOM/ES/1992/LLM373AJ620631.1**.**T**.**R**MON-201MHOM/IT/93/ISS822MF288915**--**.**----MON-228MHOM/IT/1994/ISS1036AJ620632.1**.**K**..**MON-267MHOM/SD/1997/LEM3472^a^AJ620634.1C**.**T**.**Zymodeme sequences obtained in this study are in bold*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]Table 7Polymorphisms in glucose-6-phosphate dehydrogenase (*g6pdh*)ZymodemeStrain/isolateGenBank ID453153483594034686901191MON-1MHOM/FR/78/LEM75DQ449770.1TCTAGTCCMON-1MHOM/PT/2000/IMT260DQ449775.1**........**MON-1MHOM/ES/1986/BCN16DQ449774.1**........**MON-1MHOM/FR/1997/LSL29DQ449773.1**...**W**....**MON-1MHOM/ES/1993/PM1DQ449772.1**........**MON-1MHOM/FR/1995/LPN114DQ449771.1**........**MON-1MHOM/BL/67/ITMAP263KU175220.1--**.......MON-1MHOM/TN/80/IPT1MF479731.......**--**MON-1MHOM/FR/78/LEM75MF479732.**--------**..**--**MON-1Isolate 49uMF479733.......**--**MON-1Isolate 31UMF479734...**------**.**--**MON-1Isolate 791MF479735.......**--**MON-1Isolate 10816MF479736.......**--**MON-1Isolate V2921MF479737.......**--MON-11MHOM/FR/1980/LEM189DQ449783.1C**..**T**....MON-24MHOM/DZ/82/LIPA59MF479738**C**......**--**MON-29MHOM/ES/82/BCN1MF479739**C**..**T**...**--MON-29MHOM/FR/1996/LEM3249DQ449776.1C**..**W**...**--**MON-72MHOM/IT/86/ISS218MF479740.......**--MON-77MCAM/ES/86/LEM935DQ449797.1**...**W**...**--MON-78MHOM/MT/1985/BUCKDQ449784.1C**.......**MON-81MHOM/SD/1962/3S^a^DQ449787.1CGC**...**TTMON 105MHOM/ES/2001/LLM1026DQ449799.1**........**MON-183MHOM/ES/1991/LEM2298DQ449777.1**...**W**....**MON-188MHOM/IT/1993/ISS800DQ449791.1C**.......**MON-198MHOM/ES/1988/LLM175DQ449788.1C**..**T**....**MON-199MHOM/ES/1992/LLM373DQ449789.1**...**W**....MON-201MHOM/IT/93/ISS822MF479741........**MON-228MHOM/IT/1994/ISS1036DQ449790.1**........**MON-253MHOM/ES/1996/LLM580DQ449798.1**....**A**...**MON-267MHOM/SD/1997/LEM3472^a^DQ449792.1CGC**...**TTMON-267MCAN/SD/2000/LEM3988KU175214.1--GC**...**T**.**MON-309ITOB/TR/2005/CUK2EU545237.1C**.......**MON-309MHOM/TR/2005/CUK1EU545236.1C**.......**niITOB/TR/2007/CUK10EU545238.1C**.......**niMHOM/CN/93/KXG-XUJX021334.1--**.**C**..**C**..**niMHOM/CN/94/KXG-LIUJX021333.1--**.**C**..**C**..**non-MON-1MHOM/TR/2000/OG-VLEU545239.1**........**niIsolate RRR-BDQ449796.1**........**niMHOM/PA/78/WR285KU175216.1--**.......**niIsolate D38KU175221.1--**.......**niIsolate D33KU175219.1--**.......**niIsolate D36DKU175218.1--**.......**niIsolate E9DKU175217.1--**.......**niJPCM5XM_001468358.1**........**Zymodeme sequences obtained in this study are in bold*Abbreviation*: *ni* not indicated*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]Table 8Polymorphisms in mannose phosphate isomerase (*mpi*)ZymodemeStrain/isolateGenBank ID300392486637798MON-1MHOM/FR/1978/LEM75DQ449737.1CAGACMON-1MHOM/FR/1995/LPN114DQ449738.1**.....**MON-1MHOM/ES/1993/PM1DQ449739.1**.....**MON-1MHOM/FR/1997/LSL29DQ449740.1**.....**MON-1MHOM/ES/1986/BCN16DQ449741.1**.....**MON-1MHOM/PT/2000/IMT260DQ449742.1**.....MON-1MHOM/TN/1980/IPT1MF462101.....MON-1MHOM/FR/78/LEM75MF462102.**----**..MON-1Isolate 31uMF462103.....MON-1Isolate 791MF462104.....MON-1Isolate 10816MF462105..**--**..MON-1Isolate V2921MF462106.....MON-1Isolate 49uMF462107.....**MON-11MHOM/FR/1980/LEM189DQ449750.1**.....MON-24MHOM/DZ/82/LIPA59MF462108.....MON-29MHOM/ES/81/BCN1MF462109.....**MON-29MHOM/FR/1996/LEM3249DQ449743.1**.....MON-72MHOM/IT/86/ISS218MF462110.....**MON-78MHOM/MT/1985/BUCKDQ449751.1**.....**MON-81MHOM/SD/1962/3S^a^DQ449754.1**.....**MON-136MHOM/IT/1990/ISS510DQ449766.1**..**AR**.**MON-183MHOM/ES/1991/LEM2298DQ449744.1**.....**MON-188MHOM/IT/1993/ISS800DQ449758.1**...**G**.**MON-198MHOM/ES/1988/LLM175DQ449755.1**.....**MON-199MHOM/ES/1992/LLM373DQ449756.1**.....MON-201MHOM/IT/93/ISS822MF462111...**R**.**MON-228MHOM/IT/1994/ISS1036DQ449757.1**.....**MON-267MHOM/SD/1997/LEM3472^a^DQ449759.1TR**..**Tnon-MON-1MHOM/TR/2000/OG-VLEU545251.1**.....**niMHOM/TR/2005/CUK1EU545248.1**.....**niITOB/TR/2005/CUK2EU545249.1**.....**niITOB/TR/2007/CUK10EU545250.1**.....**niMHOM/CN/94/KXG-LIUJX021373.1T**...**TniMHOM/CN/93/KXG-XUJX021374.1T**...**TniIsolate RRR-BDQ449763.1Y**...**YZymodeme sequences obtained in this study are in bold*Abbreviation*: *ni* not indicated*Key*: **.** consensus sequence, -- sequence not available^a^Initially assigned to *L. infantum* and successively designated *L. donovani* \[[@CR18]\]

The concatenated partial sequences for *me*, *pgd*, *icd*, *gpi*, *g6pdh*, *mpi* from 23 strains were used for phylogenetic tree construction (Fig. [1](#Fig1){ref-type="fig"}, Additional file [2](#MOESM2){ref-type="media"}: Table S1). The tree showed a 100% bootstrap support for the *L. infantum* strains and a 75% support for the clade including all strains of MON-1, 72, 201 zymodemes. Within this clade, the MHOM/TN/80/IPT1 strain differed from the bulk of closely related strains (bootstrap support value of 66%) (Fig. [1](#Fig1){ref-type="fig"}). This made it possible to identify the most common genotypes in Europe using a simple screening method (see below).Fig. 1Phylogenetic tree of 23 strains based on the multilocus sequence data. The sequencing data for six genes (*me*, *pgd*, *icd*, *gpi*, *g6pdh*, *mpi*) were used to build a 3578 bp long sequence. The tree was constructed using the Maximum Likelihood method based on the GTR+I model using PhyML 3.0 software. Bootstrap values were calculated from 100 replications. Numbers below branches represent bootstrap support

Exploiting sequence polymorphisms for typing {#Sec9}
--------------------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, the clade including zymodemes MON-1, 72, 201 could be discriminated from all other zymodemes with the exception of the MHOM/TN/80/IPT1 strain. The sequence comparison analysis showed that this group could be discriminated by exploiting the polymorphism 390T\>G in the *me* gene sequence (Table [3](#Tab3){ref-type="table"}). In fact, MON-1, 72, 201 present a T in position 390 (genotype 390T), while the other zymodemes present a G (genotype 390G). Due to this observation, we developed a HRM-based assay to monitor the SNP at position 390. To this end, two internal primers were designed upstream and downstream nucleotide 390, and used for a new qPCR assay (qPCR-MEint) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a). The qPCR-MEint showed a linear correlation between the log of DNA concentration (from 2 to 2 × 10^-5^ ng/reaction) and Ct values, with a reaction efficiency of 90% (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Linear correlation between the log of DNA concentration and Ct values. The qPCR-MEint curve was obtained amplifying serial dilutions of genomic DNA (from 2 to 2 × 10^-5^ ng/reaction tube) purified from *L. infantum* MHOM/FR/78/LEM75 (y = -3.59x + 20.58). Each reaction was performed in triplicate. Reaction efficiency = 90%, *R*^2^ = 0.996

HRM analysis allowed us to distinguish amplicons with genotype 390G (i.e. MHOM/TN/80/IPT1 and MHOM/DZ/82/LIPA59 strains) from amplicons with genotype 390T (i.e. MHOM/FR/78/LEM75 and MHOM/IT/86/ISS218 strains) (Fig. [3a](#Fig3){ref-type="fig"}). Furthermore, using the PCR product from strains MHOM/DZ/82/LIPA59 and MHOM/FR/78/LEM75 as reference, two *L. infantum* clinical isolates (isolate 1 and 2) \[[@CR32]\] were typed with qPCR-MEint followed by HRM analysis. The HRM analysis tool of Rotor-Gene 6000 software allowed for the assignment of amplicons of clinical isolate 1 and 2 to genotype 390G and genotype 390T, respectively, with a confidence \> 95% in at least one replicate (Fig. [3b](#Fig3){ref-type="fig"}). These results have been confirmed by PCR product sequencing (Additional file [3](#MOESM3){ref-type="media"}: Figure S2).Fig. 3HRM analysis of amplicons with genotypes 390G and 390T. **a** HRM profiles obtained from qPCR-MEint amplicons of strains MHOM/TN/80/IPT1 and MHOM/DZ/82/LIPA59 (genotype 390G) and amplicons of strains MHOM/FR/78/LEM75 and MHOM/IT/86/ISS218 (genotype 390T). **b** The analysis of HRM profiles allowed the assignation of amplicons of clinical isolates 1 and 2 to genotypes 390G and 390T, respectively, with a confidence \> 95% in at least one replicate. Strains MHOM/DZ/82/LIPA59 (genotype 390G) and MHOM/FR/78/LEM75 (genotype 390T) were used as reference. Analyses were performed in duplicates

Application of HRM analysis in clinical samples {#Sec10}
-----------------------------------------------

To test the feasibility of the HRM-based typing approach without parasite cultivation, the qPCR-MEint followed by HRM analysis was performed using DNA extracted from canine clinical samples \[[@CR31], [@CR33]\] and a human clinical sample (blood), using PCR product from strains MHOM/DZ/82/LIPA59 and MHOM/FR/78/LEM75 as reference. The human peripheral venous blood sample was obtained during routine diagnosis of a patient with VL by venipuncture of the upper limb. The HRM analysis allowed for the assignment of all samples to group 390T (Table [9](#Tab9){ref-type="table"}). The results were confirmed by PCR product sequencing (Additional file [4](#MOESM4){ref-type="media"}: Figure S3).Table 9HRM analysis results of clinical samplesNameGenotypeConfidence %MHOM/FR/78/LEM75390T98.02MHOM/FR/78/LEM75390T98.02MHOM/DZ/82/LIPA59390G99.90MHOM/DZ/82/LIPA59390G99.9062 bc390T85.0562 bc390T82.9977 sx390T79.4077 sx390T94.41vea bm390T97.69vea bm390T97.38Psalb390T86.23Psalb390T77.97*Abbreviations*: 62 bc, canine sample, buffy coat; 77 sx, canine sample, conjunctival swab; vea bm, canine sample, bone marrow; psalb, human sample, blood

Discussion {#Sec11}
==========

Epidemiological studies examining the dynamic balance between host, vector, and pathogen populations is an important aspect of *Leishmania* infections, and the importance of reservoirs alternative to the canine population (e.g. lagomorphs, wolves) is currently being investigated \[[@CR34], [@CR35]\]. For example, in Italy, *L. infantum* zymodemes retrieved in infected dogs are primarily represented by MON-1 and MON-72, while infection in humans is caused by a more heterogeneous zymodeme population, suggesting that the canine population is not the only reservoir for all *L. infantum* zymodemes \[[@CR15]\].

In this study, we investigated the genetic diversity within seven *L. infantum* genes, aiming to provide information that could aid in the development of tools for fast genetic characterization and epidemiological screening of *L. infantum* in mammalian host and/or vectors. In particular, we investigated whether it was possible to distinguish the genotype associated with the most common zymodemes in the Mediterranean area (i.e. MON-1 and MON-72), from the genotype associated with all other zymodemes, therefore limiting the number of samples needing costly and time-consuming characterizations. To this end, we collected and aligned all *L. infantum* gene sequences of seven enzymes (*me*, *pgd*, *icd*, *gpi*, *g6pdh*, *mpi*, *pgm*) available in GenBank to identify the regions that were more polymorphic. These regions were amplified in 11 other *L. infantum* strains available in our laboratory to increase the number of sequences to compare. The phylogenetic analysis of the concatenated sequences showed that the group including zymodemes MON-1, 72, 201 clustered separately. Zymodeme MON-201 has been found only in some HIV-positive individuals \[[@CR12], [@CR36]\] and in one case of feline leishmaniasis \[[@CR37]\]; therefore, its retrieval may be considered rare. Notably, the genetic distance of MON-81 and MON-267 from other *L. infantum* zymodemes was confirmed (Fig. [1](#Fig1){ref-type="fig"}, Additional file [2](#MOESM2){ref-type="media"}: Table S1). In fact, MON-81 and MON-267, initially considered *L. infantum*, have been successively assigned to *L. donovani* \[[@CR18]\].

Remarkably, the silent polymorphism at position 390 (T/G) of the *me* gene distinguishes strains of MON-1, 72, 201 (genotype 390T) from strains of other zymodemes (genotype 390G) (Table [3](#Tab3){ref-type="table"}). This could be important for epidemiological applications, as MON-1 is the most common zymodeme of *L. infantum* in Europe. The only exception was the reference strain MHOM/TN/80/IPT1, which presents a guanine at nucleotide 390. This may be due to the geographical origin of this strain (Tunisia) compared to the European strains/isolates. It is also noteworthy that, among the MON-1 strains, only strain MHOM/TN/80/IPT1 cannot be distinguished from the MON-98 strains (considering that only *me* sequences were available for this MON) (Table [3](#Tab3){ref-type="table"}). This could be in agreement with results reported by Haralambous et al. \[[@CR24]\], which showed that some MON-1 and MON-98 zymodemes were not distinguished with a PCR-based typing method using the K26 antigen-coding gene as target sequence. Notably, the use of a real-time PCR-based assay with internal primers followed by HRM analysis allowed for the quick differentiation of sequences with the polymorphysm 390T\>G not only in *L. infantum* isolates/strains, but also in clinical samples, enabling the potential application of this approach in population screening without parasite isolation and culturing.

Many marker sequences can be taken into consideration for genotyping purposes. The most suitable marker sequence depends on the level of resolution needed: highly variable markers can distinguish closely related genotypes but may not faithfully represent more distant relationships, while moderately variable markers will not be able to evidence the differences between closely related samples. The assay that we propose would not be able to distinguish closely related genotypes; therefore, it could be used to differentiate between relapse and re-infection only in cases where different 390T/G genotypes were found. However, it could be useful for epidemiological screening in regions where MLEE data are available, to rapidly identify zymodemes different from MON-1, 72 or 201 (e.g. for rapid screening of *L. infantum* genotypes in mammalian hosts). Once attributed a genotype (390T or 390G), other tests (e.g. MLEE or MLST) can be performed, depending on the level of resolution needed and on the classification system with which the results are to be compared.

Other zymodemes (i.e. MON-24, MON-78 and MON-199) could be identified by exploiting the unique SNP found across the seven gene sequences. In particular MON-24, which is another common zymodeme \[[@CR12], [@CR38]\], could be differentiated by exploiting the polymorphisms 204T\>C in the *icd* gene (Table [5](#Tab5){ref-type="table"}) by using a HRM-based assay similar to the assay described here.

A possible limitation of this study is the unavailability of some zymodeme sequences in the database. Moreover, in many cases, only one strain with sequence information per zymodeme was available. This is important to keep in mind, since strains of the same zymodeme could present different genotypes (e.g. MON-29 in *me*, *icd* and *g6pdh* genes) (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

Conclusions {#Sec12}
===========

A total of 77 new sequences of seven genes encoding for metabolic enzymes in *L. infantum* isolates/strains have been produced and deposited in the GenBank database. The analysis of these sequences, together with sequences available in the database, allowed for the identification of genetic polymorphisms exploitable to differentiate the most common *L. infantum* zymodemes in the Mediterranean basin. In particular, a HRM-based assay aimed to differentiate the genotype 390T and 390G in the *me* gene was developed. The genotype 390T correlated with zymodemes MON-1, 72, 201, allowing for the rapid identification of the majority of *L. infantum* genotypes. Once a parasite is attributed to genotype 390T or 390G, other tests (e.g. MLEE, MLST or MLMT) can be performed if more detailed information is needed. This assay has been successfully applied to clinical samples, demonstrating its potential applicability in investigating the role of other mammalian hosts in epidemiological screening.

Additional files
================

 {#Sec13}

Additional file 1:**Figure S1.** Reference sequences and position of primers used in this study. **a** *L. infantum* strain MHOM/FR/1978/LEM75 cytosolic NADP-malic enzyme (me) gene, partial cds. (GenBank: DQ449701.1). Primers amplifying 5\' region and 3\' region are boxed and underlined, respectively. Internal primers are in bold. **b** *L. infantum* gene for phosphogluconate dehydrogenase (decarboxylating), strain MHOM/FR/1978/LEM75 (GenBank: AM157139.1). **c** *L. infantum* strain MHOM/FR/1978/LEM75 mitochondrial isocitrate dehydrogenase (icd) gene, complete cds (GenBank: DQ449672.1). **d** *L. infantum* gpi gene for glucose-6-phosphate isomerase, strain MHOM/FR/1978/LEM75 (GenBank: AJ620617.1). **e** *L. infantum* strain MHOM/FR/1978/LEM75 glucose-6-phosphate dehydrogenase (g6pdh) gene, complete cds (GenBank:DQ449770.1). **f** *L. infantum* strain MHOM/FR/1978/LEM75 mannose phosphate isomerase (mpi) gene, complete cds (GenBank: DQ449737.1). **g** *L. infantum* isolate MCAN/AR/10/MDP1 phosphoglucomutase gene, partial cds (GenBank: KJ643214.1). (DOCX 20 kb) Additional file 2:**Table S1.** Summary of allelic profile and genotype of *L. infantum* zymodemes considered in this study. (DOCX 18 kb) Additional file 3:**Figure S2.** Partial sequences of qPCR-MEint amplification products from reference strains and clinical isolates. Electropherograms encompassing polymorphic nucleotide at position 390 (arrows) are represented. (PDF 72 kb) Additional file 4:**Figure S3.** Partial sequences of qPCR-MEint amplification products from clinical samples. Electropherograms encompassing polymorphic nucleotide at position 390 (arrows) are represented. (PDF 570 kb)

qPCR

:   Quantitative real-time PCR

VL

:   Visceral leishmaniasis

CL

:   Cutaneous leishmaniasis

HRM

:   High-resolution melting

MLEE

:   Multilocus enzyme electrophoresis

MLST

:   Multilocus sequence typing

MLMT

:   Multilocus microsatellite typing
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